Abstract:Background: Accurate interpretation of BRCA1/2 variants is critical for risk assessment, enhanced cancer surveillance, prevention strategies, and precise clinical treatment of breast cancer. However, current worldwide standards depend primarily on sequencing information from Caucasian populations.Methods: Panel-based sequencing served to detect BRCA1/2 variants in a Chinese multicenter cohort of 21,216 breast cancer patients (BCs) and 6,434 healthy controls (HCs).Findings: 1,245 pathogenic variants of BRCA1/2, 262 of which were novel (21.04%), and 2,517 variants of uncertain significance (VUS) were identified. Unlike in the Caucasian population, BRCA2 variants were more frequent than BRCA1 variants (56.34% versus 43.66%). The 48 most common variants accounted for 39.86% of all pathogenic variants, and were not reported as common variants in Caucasians. Furthermore, we unambiguously reclassified VUS in 508 subjects, lowering the VUS ratio from 9.05% to 7.21%. Pathogenic BRCA1/2 variants correlated with younger onset age, higher frequencies of bilateral and triple-negative BC, invasive carcinomas, high histological grades, and family history of BC and other cancers.Interpretation: Strong ethnicity-specific occurrences of pathogenic BRCA1/2 variants were identified in the Chinese population. Hence, the findings provide rationale and sequencing information for the implementation of BRCA1/2 variants tailored to the Chinese population into clinical risk assessment.Funding Statement: National Natural Science Foundation of China 81772802, Shanghai science and technology innovation action plan of China 17JC1404400 and 16DZ19102, Special Funds for Technological Innovation of Shanghai Jiao Tong University YG2016MS22, Chinese Academy of Science XDA12020223 (W.H.X), Natural Science Foundation of Zhejiang Province LZ16H160002 (C.Y.D), Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talents (C.Y.D).Declaration of Interests: Authors declare no potential conflicts of interest.Ethics Approval Statement: The study was approved by the Ethics Committee of all the hospitals involved and was performed according to the Declaration of Helsinki Principles. Written consent to notify blood samples for future research was obtained for each patient under the Institutional Review Board (IRB)-approved protocol.

Identification of a Novel Germline BRCA2 Variant in a Chinese Breast Cancer Family

Prevalence and Reclassification of BRCA1 and BRCA2 Variants in a Large, Unselected Chinese Han Breast Cancer Cohort

[Analysis of the Mutations of BRCA1 in 9 Familiar Breast Cancer Patients].

Identification of <i>BRCA1</i>:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients

Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing

A Novel Loss-Of-Function Heterozygous Brca2 C.8946_8947delag Mutation Found in A Chinese Woman with Family History of Breast Cancer

Assessing the Variations in Breast/Ovarian Cancer Risk for Chinese BRCA1/2 Carriers

Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes.

Clinical characteristics and genetic analysis of a case of a patient with familial hereditary breast cancer: a case report

[BRCA1 Germ Line Mutations in Chinese Early-Onset Breast Cancer Patients].

Identification of Recurrent Variants in BRCA1 and BRCA2 Across Multiple Cancers in the Chinese Population

Identifying a BRCA2 C.5722_5723del Mutation in a Han-Chinese Family with Breast Cancer

Four novel BRCA variants found in Chinese hereditary breast cancer patients by next-generation sequencing

A Novel Germline Mutation of BRCA1 and Integrated Analysis with Somatic Mutation in a Chinese Multi-Cancer Family.

Prevalence and Characterization of BRCA1 and BRCA2 Germline Mutations in Chinese Women with Familial Breast Cancer

Identification and characterization of two novel germ line p53 mutations in the non-LFS/non-LFL breast cancer families in Chinese population

Germline Variants in 32 Cancer-Related Genes among 700 Chinese Breast Cancer Patients by Next-Generation Sequencing: A Clinic-Based, Observational Study.

Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer

Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2 -negative breast cancer patients

Identification of a Novel Breast Cancer-Causing Mutation in the BRCA1 Gene by Targeted Next Generation Sequencing: A Case Report.

Novel Loss-of-function Mutation in BRCA2 Gene Identified in a Chinese Female with a Family History of Ovarian Cancer: A Case Report